Tag Archive for: Resolution Therapeutics

Resolution Therapeutics extends inflammatory and fibrotic disease pipeline with in vivo Regenerative Macrophage Therapy

/in

Material Transfer Agreements provide access to leading lipid nanoparticle formulations to validate delivery of its proprietary payloads and accelerate development of in vivo Regenerative Macrophage Therapy  Development programme complements Company’s autologous engineered Regenerative Macrophage Therapy, RTX001, in Ph 1/2 clinical development Together, programmes aim to broaden patient population able to benefit from Regenerative Macrophage Therapy  […]

Read more

Weekly Roundup: Commercial expansion, collaborations & clinical progress

/in

Despite the short Bank Holiday week, it’s as busy as ever. Collaborative expansion is in full swing as Bonito Biosciences and DaltonTx join forces, and ViCentra triples Kaleido consumables production capacity through Phillips Medisize partnership. Hansa Biopharma, Poolbeg Pharma and Synklino have been enjoying progress this week, as Hansa reports positive efficacy and safety results […]

Read more

Resolution Therapeutics congratulates University of Edinburgh on positive 4-year MATCH trial data on RMT in liver cirrhosis

/in

Results support progression of EMERALD clinical trial of Resolution’s engineered macrophage therapy, RTX001 Four-year follow-up data from the University of Edinburgh’s MATCH study, led by Resolution Therapeutics’ founder Professor Stuart Forbes, published in the journal Cell Stem Cell Resolution is pioneering engineered Regenerative Macrophage Therapy – which uses engineered macrophages designed to deliver a more […]

Read more

Weekly Roundup: Patents, presentations and preclinical data

/in

Riding the wave of BioEquity, it has been another busy week for Optimum’s clients. Hansa Biopharma, Poolbeg Pharma and Resolution Therapeutics are all taking to the stage across Europe and the US. Optimum’s own Stephen Adams will be chairing a panel at LSX Nordic next week after yet another fascinating Hot Topic – this time […]

Read more

Weekly roundup: Awards, events, financings and 2 new episodes of Optimum TV

/in

R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease R1 Therapeutics, Inc, a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with kidney disease, announced its launch with an oversubscribed $77.5 million Series A financing, along with the […]

Read more
© Optimum Strategic Communications.